ALPS Medical Breakthroughs ETFSBIO
SBIO
0
Funds holding %
of 6,810 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
3.29% more ownership
Funds ownership: 49.15% [Q2] → 52.44% (+3.29%) [Q3]
5% more capital invested
Capital invested by funds: $50.7M [Q2] → $53M (+$2.29M) [Q3]
3% less funds holding
Funds holding: 38 [Q2] → 37 (-1) [Q3]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
Research analyst outlook
We haven’t received any recent analyst ratings for SBIO.
Financial journalist opinion
Negative
Seeking Alpha
3 weeks ago
SBIO ETF: Betting On Medical Breakthroughs
ALPS Medical Breakthroughs ETF is rated Hold due to high fees, low yield, and mixed performance compared to other healthcare ETFs. The SBIO ETF focuses on small and mid-cap biotech companies with drugs in Phase II or III FDA trials, offering targeted exposure to medical breakthroughs. Despite an aging population driving healthcare demand, sector headwinds and government budget pressures make healthcare stocks less attractive for generating Alpha.
Positive
ETF Trends
1 month ago
Biotech Looms as a Way to Beat the Market
Could now be the time to diversify into important tech subsectors? Rate cuts may already be benefiting tech sectors by easing borrowing costs, with more cuts potentially in the offing.
Positive
ETF Trends
1 month ago
Disruptive Theme of the Week – Breakthroughs in Medicine
Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.
Positive
ETF Trends
1 month ago
Steady Rate Cuts Feed Surging Biotech ETF SBIO
Yet another rate cut has come and gone, and even with somewhat steady inflation reads, further cuts may be in the pipeline. Debt-heavy areas like tech stand to benefit, but for those already heavily exposed to big tech names, looking elsewhere may appeal.
Positive
ETF Trends
1 month ago
How Election Results Could Impact Biotech ETFs
Biotech stocks and ETFs are among the assets that responded positively to last week's presidential election results. As just one example, the ALPS Medical Breakthroughs ETF (SBIO) is up 10% for the week ending November 11.
Positive
ETF Trends
2 months ago
Biotech ETF SBIO Laps Tech Rivals Over 1 Year
If there were a defining sector for investors this year, it has been tech investing. The ascendance of AI has lifted valuations and investor portfolios, boosting the market as a whole.
Neutral
Business Wire
3 months ago
Advacam & Vector Space Biosciences sign Letter of Intent (LOI) to Develop AI Models & CubeSat Payloads for the Space Industry
LA JOLLA, Calif.--(BUSINESS WIRE)---- $SBIO #Advacam--Advacam, provider of radiation detectors that map radiation aboard the International Space Station (ISS) and Vector Space Biosciences (crypto symbol: SBIO), with offices in Dubai and provider of AI models for data generated in the new space industry economy, have signed a Letter of Intent (LOI) to partner on joint satellite payload design and development of CubeSats along with measuring radiation and launching payloads for biotechnology, pharmaceutical compani.
Positive
ETF Trends
3 months ago
Tailwinds Emerging for This Biotech ETF
The effects of the Federal Reserve's recent interest rate cut haven't fully been felt by the economy or financial markets. But the first instance of U.S. monetary easing in over four years may be a boon for capital-intensive biotech companies.
Positive
ETF Trends
4 months ago
Biotech Stocks Are Perking Up. This ETF Is Responding
In a somewhat quiet fashion, long-lagging biotech stocks and exchange traded funds are perking up. The ALPS Medical Breakthroughs ETF (SBIO) is part of that group.
Positive
ETF Trends
4 months ago
VettaFi Is Finalist for 4 ETF Awards
The TMX VettaFi business segment is less than a year old, but it is already getting recognized for the breadth of its capabilities. Last week, we were named a finalist by ETF Express in four award categories.
Charts implemented using Lightweight Charts™